Biopôle-based Testmate Health and Intermountain Health have announced a strategic partnership and investment to accelerate access to rapid, low-cost molecular tests for sexually transmitted infections (STIs) in the U.S. Set to become a shareholder in Testmate, Intermountain Health will support the company in clinical validation and trials until FDA approval.
First-of-its-kind partnership and investment brings lab-quality STI diagnostics to decentralized care settings, addressing a silent public health crisis.
STIs remain a largely silent epidemic, with 80% of chlamydia and gonorrhea infections going undiagnosed each year. Populations most affected include college students, LGBTQ+ communities, and rural or low-resource clinics face significant barriers to timely testing and treatment. This partnership and investment directly address that gap by bringing high-accuracy, low-cost diagnostics to the people and places that need them most.
